Novel p2x7r antagonists and their use

A method for the treatment of a disease or disorder mediated by P2X7R or IL-1 in a patient comprising administering to the patient a therapeutically effective amount of a compound of the general formula:

• or a pharmaceutically acceptable salt or solvate thereof;
• wherein,
• R1 is a mono- or bi-cycloalkylalkyl group or mono- or bi-cycloalkyl group;
• R2 is selected from straight or branched C1-C5 alkyl which may optionally substituted with —OH, —CH2—OH, C1-C5 alkoxy, N(Ra)2—, NHRa—, CN—, CF3, halogen, piperidino, morpholine, pyrrolidino, 5H-tetrazolylpropyl, methylcarbamoyl, dimethylcarbamoyl, or ethylmethylcarbamoyl, wherein Ra is C1-C5 alkyl;
• R3, R4, R5, R6 are at each occurrence independently selected from hydrogen, halogen (i.e. Cl, F, Br or I), methyl, methoxy, cyano, or trifluoromethyl;
• and
• a, b, c, d, x are at each occurrence independently selected from carbon, or nitrogen.